Dazostinag disodium (TAK-676) is a synthetic novel interferon gene (STING) agonist that triggers STING signaling pathway activation and type I interferon activation. Dazostinag disodium (TAK-676) is also a highly effective immune system modulator with complete resolution and lasting memory of T cell immunity and the ability to promote lasting interferon-dependent anti-tumor immune responses.

METHODS: The ability of TAK-676 to activate the STING pathway was evaluated in human THP1-Dual and mouse CT26 cells treated with dazostinag disodium (TAK-676) (1.1, 3.3, 10 μM, 2 hours).
RESULTS Expression of pSTING (S366), pTBK1 (S172), and pIRF3 (S396) was dose-dependently induced in both mouse and human cell lines. [1]

METHODS: Mice were injected subcutaneously into the right flank with CT26, WT tumor cells, A20 tumor cells, or B16F10 tumor cells, and Dazostinag disodium (TAK-676) (0.3, 1.0, 2.0 mg/kg, intravenously, once every three days, 3 times), and the effects on tumor growth were evaluated by measuring growth rate inhibition (GRI) and tumor regression.
RESULTS When Dazostinag disodium (TAK-676) was administered at a dose of 1 mg/kg, BALB/c mice bearing A20 syngeneic tumors showed significant antitumor activity compared to vehicle treatment (GRI 72%, P < 0.001); similar to the A20 tumor model, CT26 tumor-bearing animals treated with 1 mg/kg of Dazostinag disodium (TAK-676) also showed tumor control over vehicle-treated animals; when the dose of Dazostinag disodium (TAK-676) was increased from 1.0 to 2.0 mg/kg, the antitumor activity was significantly increased in both the A20 (GRI=91%, P < 0.001) and CT26 (GRI=132%, P < 0.001) models. [1]